Evidence map›Paper›PMID 41635843›Full record

ArticleFrontiers in immunology2025

Adjunctive GM-CSF therapy enhances host defense against systemic

Eliciane Cevolani Mattos, Kaustav Das Gupta, Derek Quintanilla, Haley Hautau, Ashraf S Ibrahim, Shakti Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eliciane Cevolani Mattos *Division of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.
Kaustav Das Gupta *Division of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.
Derek QuintanillaDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.
Haley HautauDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.
Ashraf S IbrahimDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.
Shakti SinghDivision of Infectious Disease, The Lundquist Institute for Biomedical Innovation at Harbor-University of California, Los Angeles Medical Center, Torrance, CA, United States.

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Role of multi-drug resistant Candida auris Hyr1 / Iff-like proteins in virulence and their potential as vaccine targetsK01AI180591 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Shakti Singh · 2024 to 2026
$405k
American Heart Association-American Stroke Association 938451NCATS NIH HHS KL2 TR001882NIAID NIH HHS K01 AI180591
6 · The paper itself

Abstract

Introduction: Methods: Immunosuppressed ICR CD-1 mice (4-6 weeks old) were infected with Results: GM-CSF monotherapy significantly improved survival (30-32% vs. 0% in controls), extended median survival time, and reduced fungal burden in the kidney, heart, and brain. Although the combination therapy yielded the highest survival rate, it did not differ significantly from GM-CSF alone. Histopathological examination confirmed decreased fungal load and tissue damage in GM-CSF-treated mice. Additionally, GM-CSF augmented macrophage and neutrophil populations in spleen and kidney, enhanced fungal uptake and killing via reactive oxygen species and neutrophil extracellular traps. Discussion: GM-CSF augments antifungal immunity and represents a promising adjunctive immunotherapy against MDR

Indexed as

Antifungal AgentsCandida aurisCandidiasisGranulocyte-Macrophage Colony-Stimulating FactorImmunocompromised HostAnimalsCandidiasis, InvasiveDisease Models, AnimalHost-Directed TherapyMacrophagesMicafunginMiceMice, Inbred ICRNeutrophilsAntifungal AgentsGranulocyte-Macrophage Colony-Stimulating FactorMicafunginantifungal immunityCandida aurisGM-CSFImmunosuppressionimmunotherapymacrophage, neutrophilsmurine systemic infection model

Identifiers

PMID41635843
PMCPMC12862068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.